Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct

D S Franklin1, V L Godfrey, D A O'Brien

  • 1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7295, USA.

Insights

Losing two cyclin-dependent kinase (CDK) inhibitor genes, p18 and p27, caused multiple hyperplastic tissues and tumors in mice. This suggests CDK inhibitors are crucial tumor suppressors with tissue-specific functions.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Mammalian cyclin-dependent kinase (CDK) inhibitor genes regulate cell cycle control.
  • Distinct tissue expression patterns suggest CDK inhibitors may act as tissue-specific tumor suppressors.

Purpose of the Study:

  • To investigate the in vivo function of CDK inhibitors as tumor suppressors.
  • To characterize the effects of combined loss of specific CDK inhibitors on tumor development.

Main Methods:

  • Generated and analyzed double mutant mice lacking p18(INK4c) and p27(KIP1) or p18(INK4c) and p21(CIP1/WAF1).
  • Assessed spontaneous tumor development and characterized tissue hyperplasia.
  • Measured G(1) CDK2 and CDK4 kinase activities in normal and neoplastic tissues.

Main Results:

  • Loss of p18 and p27 led to spontaneous development of at least eight hyperplastic tissues/tumors by 3 months, primarily in endocrine organs.
  • p18-p21 double null mice developed pituitary adenomas, gastric neuroendocrine hyperplasia, and lung tumors later in life.
  • Simultaneous loss of two CDK inhibitors synergistically increased G(1) CDK kinase activity, which is critical but insufficient for tumor growth.

Conclusions:

  • Functional collaborations between distinct CDK inhibitor genes are tissue-specific.
  • CDK inhibitors provide a regulatory layer for cell growth control and tumor suppression.
  • Increased G(1) CDK kinase activity is a necessary but not sufficient event in tumor development.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...